What is the commercial market opportunity for 4DMedical (ASX:4DX) following this news?

The breakthrough targets a lucrative US$2.5 billion market entry into the acute pulmonary embolism sector[cite: 1]. This initiative expands 4DMedical’s total obtainable US market value to an estimated US$3 billion by capitalising on both the traditional nuclear VQ sector and the larger CTPA-dominated imaging market.

What problem in the US healthcare system is 4DMedical (ASX:4DX) trying to solve?

Pulmonary embolism accounts for 600,000 to 650,000 diagnosed clinical episodes in America annually, leading to emergency over-imaging due to high mortality risks. Roughly 5 million CTPA scans are performed each year, yet they demonstrate a remarkably low diagnostic positive yield of just 3% to 10%.

Why is 4DMedical’s CT:VQ technology considered a disruptive solution for retail investors?

Current standard CTPA imaging results in up to 97% of patients being routinely subjected to high-cost imaging and invasive iodinated contrast exposure without confirmation of PE. 4DMedical's CT:VQ offers a contrast-free alternative, potentially cutting unnecessary exposure and high healthcare costs if the clinical validation succeeds.

What are the key details of 4DMedical’s CLEAR clinical trial?

The CLEAR programme—standing for Contrast-free Lung Evaluation for Acute Risk—is a comprehensive multi-centre, multinational, prospective observational study. The trial will pit 4DMedical’s CT:VQ technology head-to-head against standard Computed Tomography Pulmonary Angiography (CTPA) in patients with suspected PE.

Image for illustrative purposes only. Not a real photo.

4DMedical targets US$2.5B pulmonary embolism market

Q: What did 4DMedical (ASX:4DX) announce regarding its US market expansion?

4DMedical announced the launch of CLEAR, a clinical evidence programme designed to fast-track its proprietary CT:VQ™ technology into the acute United States pulmonary embolism (PE) market.

Written by Heidi Cuthbert Published Jun. 2 2026Last Updated Jun. 2 2026

4DMedical (ASX:4DX) announced the launch of CLEAR, a clinical evidence programme designed to fast-track its proprietary CT:VQ technology into the acute United States pulmonary embolism market.

The breakthrough targets a US$2.5 billion market entry, effectively expanding the medical tech company's total obtainable US market value to an estimated US$3 billion by capitalising on both the traditional nuclear VQ sector and the substantially larger CTPA-dominated imaging market.

The CLEAR programme—standing for Contrast-free Lung Evaluation for Acute Risk—centres on a comprehensive, multi-centre, multinational, prospective observational study that will pit CT:VQ head-to-head against standard computed tomography pulmonary angiography in patients with suspected PE.

4DMedical secured a milestone clinical research agreement with the prestigious Mass General Brigham-affiliated teaching hospitals to serve as the lead site for the validation initiative.

Currently, pulmonary embolism represents a critical healthcare challenge in America, accounting for roughly 600,000 to 650,000 diagnosed clinical episodes annually.

Due to high mortality risks, current emergency workflows are heavily biassed towards over-imaging, resulting in an estimated 5 million CTPA scans performed each year.

However, CTPA demonstrates a remarkably low diagnostic positive yield of just 3% to 10%.

This means up to 97% of patients are routinely subjected to high-cost imaging and invasive iodinated contrast exposure without confirmation of PE.

At the time of reporting, 4DMedical’s share price was $3.98.